Please try another search
Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.
Name | Age | Since | Title |
---|---|---|---|
Andrew Cain McClary | 38 | 2019 | Independent Director |
Leonard Milstone | - | - | Member of Scientific & Clinical Advisory Board |
Alain Hovnanian | - | - | Member of Scientific & Clinical Advisory Board |
Julia Oh | - | - | Member of Scientific & Clinical Advisory Board |
Barbara A. Ryan | 64 | 2023 | Independent Director |
John R. Schroer | 59 | 2023 | Independent Director |
Travis M. Whitfill | 34 | 2019 | Co-Founder, COO & Director |
Francisco D. Salva | 53 | 2021 | President, CEO & Director |
Edel O’Toole | - | - | Member of Scientific & Clinical Advisory Board |
Amy S. Paller | - | - | Member of Scientific & Clinical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review